Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I
Enzo Biochem, Inc. ($0.01 Par Value) (ENZ)
Last enzo biochem, inc. ($0.01 par value) earnings: 12/7 04:10 pm
Check Earnings Report
US:NYSE Investor Relations:
enzo.com/corporate/investor-information
Company Research
Source: GlobeNewswire
Continues to Explore Opportunities for Use of the Compound as a Potential Treatment for COVID-19 NEW YORK, NY, June 23, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the Treatment of Cancers. Enzo’s patent is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the company’s proprietary compound SK1-I and has a term extending into June 2038. Foreign patent applications in the same patent family are currently pending. Elazar Rabbani, Ph.D., CEO of Enzo Biochem, Inc. commented: “This new application of our proprietary compound is an important step in our program to advance SK1-I as a potential treatment for liver cancer and other cancers. Both our internal studies and the work of others have shown that SK1-I
Show less
Read more
Impact Snapshot
Event Time:
ENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENZ alerts
High impacting Enzo Biochem, Inc. ($0.01 Par Value) news events
Weekly update
A roundup of the hottest topics
ENZ
News
- Global Oxidative Stress Assay Market Analysis Report 2024-2030: Reactive Oxygen Species-based Assays Segment is Forecast to Grow at the Fastest CAGR over the Forecast Period [Yahoo! Finance]Yahoo! Finance
- Global Polymerase Chain Reaction for qPCR, dPCR, Singleplex & Multiplex Markets, 2023-2024 and 2027: Lowering Costs, Improving Outcomes and Battling Against Anti Microbial Resistance [Yahoo! Finance]Yahoo! Finance
- Enzo Biochem (NYSE:ENZ) shareholders have endured a 69% loss from investing in the stock three years ago [Yahoo! Finance]Yahoo! Finance
- Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateGlobeNewswire
ENZ
Sec Filings
- 3/13/24 - Form 8-K
- 3/13/24 - Form 10-Q
- 2/27/24 - Form 4
- ENZ's page on the SEC website